Background: Previous studies have shown that clarithromycin inhibits several
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INTRODUCTION
Periodontitis is a bacterially induced chronic inflammatory disease which leads to the destruction of the underlying structures of the teeth, such as the periodontal ligament, cementum, and bone. Most species of subgingival bacteria associated with periodontitis can be eliminated by mechanical debridement (root planing). However, some bacterial species, such as Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis, are exceptionally difficult to eliminate by mechanical therapy alone. 1 
A.
actinomycetemcomitans is a Gram-negative microaerophilic coccobacillus that is strongly associated with aggressive and refractory forms of periodontitis, while P. gingivalis is a Gram-negative anaerobic rod that is associated with severe adult periodontitis, failing guided tissue regeneration, and acute periodontal abscesses. 2, 3 Both species possess virulence factors that frustrate the host response and resist conventional efforts to eliminate them.
One such virulence factor that is prevalent in both bacterial species is the ability to invade the epithelial lining of the periodontal pocket. 4 A. actinomycetemcomitans can invade epithelial cells and pass into the underlying connective tissue, while P. gingivalis can invade epithelial cells and linger inside the cell. 5, 6 Invasion by A.
actinomycetemcomitans occurs through the binding of bacterial fimbrae or extracellular vesicles onto the cell surface. This causes ruffling and invaginations on the epithelial cell membrane, which allows the bacteria to be internalized. 7 Once inside, A.
actinomycetemcomitans induces membrane protrusions, which allow for bacterial migration into adjacent epithelial cells and connective tissue while escaping detection from host immune cells. 8, 9 Hypothetically, invisibility from immune cells may partly explain why individuals with aggressive periodontitis typically do not exhibit massive inflammation clinically. 9 While only a few bacterial pathogens are capable of invading and surviving within epithelial cells, these infections are among the most difficult to eradicate. Within this context, it is not difficult to envisage how inter-and intraepithelial invasion may lead to disease occurrence and resistance to treatment.
In addition, A. actinomycetemcomitans resists phagocytic killing by secreting low molecular-weight compounds that inhibit neutrophil chemotaxis, producing heat-stable proteins which inhibit the neutrophil's ability to produce hydrogen sulfide, and resisting defensins formed by neutrophils. [10] [11] [12] The bacteria also produces leukotoxin, a protein which induces apoptosis in polymorphonuclear cells (PMNs). PMNs are the first line of defense against bacteria near the gingival margin, and their inhibition allows for pathogenic bacteria to remain in the periodontium.
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Persistent infections by A.
actinomycetemcomitans or P. gingivalis are frequently associated with continued periodontal breakdown. 16 One study has found that the continual presence of A.
actinomycetemcomitans in periodontally treated patients increased the occurrence of recurrent periodontitis despite following a 3 month maintenance schedule. 17 Thus, the presence of the bacteria is notable not only for its ability to evade and inhibit the immune response, but also for its ability to produce further breakdown when the bacteria is sustained in the oral cavity.
Invasive pathogens can be eliminated by introducing an appropriate antimicrobial agent into invaded host cells. In cases where there is continued periodontal breakdown after scaling and root planing, antimicrobial chemotherapy is often used as an adjunct to mechanical therapy. 18 Several studies have noted the beneficial effects of systemic antibiotics in the treatment of aggressive periodontitis, such as reduced pocket depth and additional clinical attachment gains of approximately 0.45 mm. 19, 20 The combination of metronidazole and amoxicillin has been widely prescribed for aggressive periodontitis due to its consistent ability to reduce pocket depths, reduce the amount of periodontal pathogens, and increase clinical attachment gain. 21 The combination of both antibiotics is also more effective than either antibiotic alone. 22 However, beta-lactam antibiotics are poorly suited for treating intracellular infections because of their inability to penetrate mammalian cells. Amoxicillin also cannot be used for patients allergic to penicillin, with a history of cross-reactions occurring between 1-10% of all patients. [23] [24] [25] [26] Compliance may also be an issue, as the antibiotics must be taken together three times a day for at least seven days.
Although 
30-35
Clarithromycin is a semi-synthetic macrolide which is similar to erythromycin but demonstrates a broader spectrum of activity. It is effective towards both most grampositive bacteria and also a number of gram-negative bacteria in the oral environment.
Previous work has suggested that clarithromycin is a good candidate for treating invasive pathogens because it is accumulated inside gingival fibroblasts and epithelial cells by active transport. 36 This agent reaches higher levels in gingiva than in serum and yields higher levels in inflamed gingiva than in healthy gingiva. 37 As of now, little is known about the mechanism by which macrolide antibiotics are taken up by granulocytic cells. We hypothesized that PMNs and HL-60 cells (a human promyelocytic leukemia cell line that can be differentiated into immature PMN-like cells) possess similar active transport systems that facilitate intracellular accumulation of clarithromycin. We further hypothesized that a transporter of this type could be expected to benefit the host by enhancing the phagocytic killing of A. actinomycetemcomitans.
These two hypotheses were tested in the present laboratory study. CA) at densities of 5 x 10 6 cells/ml and 10 7 cells/ml, respectively, for the transport assays and phagocytic killing assays described below.
MATERIALS AND METHODS
HL
Clarithromycin transport: Clarithromycin transport was assayed by measuring cellassociated radioactivity over time as previously described. minutes at 37° C to facilitate phagocytosis. At the beginning of the incubation and every 30 minutes thereafter, aliquots were removed and diluted in sterile water to lyse the PMNs. After further dilution, the samples were spread on BHI agar plates and incubated for 48 hours at 37° C in 10% CO 2 . Surviving A. actinomycetemcomitans colonies were counted to assess bacterial killing. Assays were conducted at bacteria-to-PMN ratios of 30:1 and 100:1. Half-times for killing were calculated as previously described.
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RESULTS
Undifferentiated HL-60 cells took up clarithromycin from the extracellular medium in a saturable manner, reaching steady state levels within 15 minutes. Neutrophil-like HL-60 granulocytes also took up clarithromycin, although the content per cell was slightly lower and they required less time to reach steady-state than with undifferentiated cells (Fig. 1 ).
Clarithromycin uptake by HL-60 granulocytes was strongly temperature dependent and was completely inhibited at temperatures below 4º C (Fig. 1 inset) . The kinetics of uptake by HL-60 granulocytes yielded linear plots when analyzed by the LineweaverBurk method (Fig. 2, upper panel) . This analysis suggested that HL-60 granulocytes possess a transporter that can internalize clarithromycin with an estimated K m of 250 ± 7.67 µg/ml and a maximum velocity (V max ) of 473 ± 24.9 ng/min/10 6 cells.
Clarithromycin transport by human PMNs and undifferentiated HL-60 cells was also associated with linear Lineweaver-Burk plots (not shown).
In comparison to HL-60 granulocytes, PMNs transported clarithromycin with a similar K m value, and a V max value that was lower, but it was not significantly different (Table 1) .
With undifferentiated HL-60 cells, the K m and V max values for clarithromycin transport were significantly lower than with HL-60 granulocytes (P < 0.05).
HL-60 granulocytes and PMNs accumulated relatively high intracellular clarithromycin concentrations. When incubated at 37º C in medium containing 2 µg/ml clarithromycin, steady-state intracellular concentrations in HL-60 granulocytes were approximately 60 µg/ml (Table 2) . Incubation with 10 µg/ml clarithromycin yielded an intracellular concentration of 278 µg/ml. Incubation of PMNs in the presence of 2 µg/ml clarithromycin yielded an intracellular concentration of 142.6 µg/ml, while incubation with 10 µg/ml was associated with an intracellular concentration of 575 µg/ml. To determine the effect of pH on granulocyte clarithromycin transport, the kinetics of transport were analyzed over the range of pH 6.3 to pH 8.3 (Fig. 3) . Within this range, the efficiency of transport (as assessed by V max /K m ratio) exhibited a positive relationship with pH (P < 0.001, ANOVA). Transport activity was similar at pH 7.8 and 8.3, but there were significant differences in all other pairwise comparisons (P < 0.05, HolmSidak test).
When PMNs were incubated for 15 minutes in HBSS containing 5 µg/ml clarithromycin prior to their addition to a bacterial killing assay, the intracellular concentration of clarithromycin reached 290 µg/ml. The effect of clarithromycin on killing of A.
actinomycetemcomitans was dependent on the ratio of bacteria to PMNs in the assay. At a bacteria-to-PMN ratio of 100:1 (Fig. 4, upper panel) , clarithromycin-loaded PMNs killed significantly more bacteria than control PMNs at 30, 60 and 90 minutes (P < 0.05, paired t-test).
When the bacteria-to-PMN ratio was decreased to 30:1, control and clarithromycinloaded PMNs rapidly killed A. actinomycetemcomitans, while clarithromycin alone produced a more gradual pattern of inhibition (Fig. 4, lower panel) . PMNs loaded with clarithromycin killed a slightly greater number of bacteria than control PMNs, but the difference was significant only at 90 minutes (P < 0.05, paired t-test). The half-times for bacterial killing were consistent with these findings (Table 3) . Using colony-forming units (CFU) additions that yielded bacteria-to-PMN ratios of 30:1, the half-times for killing by control or clarithromycin-loaded PMNs were similar, but both were significantly shorter than with clarithromycin alone (P < 0.05, ANOVA with Holm-Sidak post test). At a bacteria-to-PMN ratio of 100:1, the half-time for killing by clarithromycin-loaded PMNs was significantly shorter than that of control PMNs (P < 0.05, ANOVA with Holm-Sidak post test), which was, in turn, significantly shorter than for clarithromycin alone (P < 0.05).
DISCUSSION
The present study characterized the uptake of clarithromycin by human cells derived it can be evident from these results that all three stages of myeloid maturation possess a transport system, and that the efficiency of the transport system is similar at several different stages of myeloid maturation. This suggests that the transporter is not highly specialized and may play an important and conserved role in cell survival.
Clarithromycin, as a weak base, could potentially be taken up by transport systems whose primary role is to scavenge nutrients and biosynthetic precursors 42, 43 . Aside from clarithromycin, other studies have found that PMNs also actively transport ciprofloxacin, doxycycline, minocycline and clindamycin 27, 40, 44 .
Although the observed affinity of the transporter is relatively low, our results suggest that transporters accumulate clarithromycin in PMNs that have migrated into periodontal pockets. In the presence of 2 µg/ml clarithromycin, a level that is easily attainable in the gingiva 37 , the transporter accumulates intracellular levels of clarithromycin that exceed 140 µg/ml. This corresponds to a level that is approximately 40-fold higher than peak serum concentrations of clarithromycin and 70-fold higher than its MIC 90 for A.
actinomycetemcomitans. 16 Clarithromycin transport also appears to be most efficient under neutral to mildly alkaline conditions. This finding is pertinent because the environment in inflamed periodontal pockets is slightly alkaline in comparison to the nearly neutral pH of healthy gingival crevices. 45, 46 Thus, conditions for clarithromycin uptake by PMNs are more favorable in a periodontal pocket than a healthy gingival crevice. In a clinical setting, this characteristic could potentially enhance the effectiveness of clarithromycin for periodontally diseased sites in both basic and acidic conditions. In a basic periodontal pocket, PMNs could readily take up antibiotics and phagocytose the bacteria at the same time, leading to efficient bacterial killing within the neutrophil. PMN killing of bacteria could potentially be enhanced in an acidic environment as well. In a periodontal abscess, where low pH is often encountered, the uptake of clarithromycin may not be very efficient, but the acidic environment could potentially trigger PMN lysis, which would release the contents of the antibiotics into the periodontal abscess and promote disease resolution.
Transporters can also move substrates in a forward or reverse direction across the plasma membrane to maintain equilibrium between the substrate concentrations in the intracellular and extracellular environments. Reverse transport allowed clarithromycinloaded HL-60 cells to release a portion of their intracellular clarithromycin pool when the concentration of clarithromycin was abruptly decreased in the extracellular medium (Fig.   2 ). It is reasonable to speculate that reverse transport could provide a mechanism by which PMNs that have migrated to inflammatory sites can help maintain effective levels of clarithromycin at these locations. 54 In an in vitro study, oral epithelial cells infected with A.
actinomycetemcomitans and P. gingivalis were incubated with up to 100-fold minimum inhibitory concentration (MIC) of several antibiotics (clindamycin, doxycyline, metronidazole, and moxifloxacin). Antibiotic treatment could not completely eradicate the intracellular bacteria, therefore viable pathogenic colonies remained. 54 In a clinical study, aggressive periodontitis patients were treated with root planing, systemic antibiotics, and chlorhexidine rinses. therapy. 21, 59 In a 5-year follow-up study of patients treated for aggressive periodontitis and maintained, 2-5% of these patients experienced recurrent episodes of loss of attachment. 60 Up to now, there are very few studies on the ability of amoxicillin and metronidazole to penetrate tissues -however, the combination may not be effective in treating intracellular infections. 55 Compared to other antibiotics, beta-lactam antibiotics demonstrate poor penetration into epithelial cells, and do not easily cross the plasma membrane. 61, 62 Furthermore, both beta-lactams and metronidazole have a limited ability to concentrate within immune defense cells such as phagocytes. [63] [64] [65] studies have demonstrated that PMNs not only take up and concentrate macrolides, but that they can also transport these antibiotics toward a chemoattractant gradient, while delaying the release of their contents until bacterial sites were reached. 28, 66 Furthermore, the concentration of clarithromycin is low in serum but can be highly concentrated within gingival tissues. 37 Our study has found that PMN transporters actively take up clarithromycin in large concentrations from the surrounding extracellular environment. There are a few limitations to the present study. First of all, only one strain of A.
actinomycetemcomitans was tested. The Y4 strain was commercially obtained and was not freshly cultivated from the oral cavity. Although the Y4 strain is a highly leukotoxic strain, there is a potential for mutation over time during storage of the bacteria.
Furthermore, although the killing half-times achieved for clarithromycin-loaded PMNs were significantly shorter compared to regular PMNs, the effect does not seem substantial. This contrasts with a similar study that tested ciprofloxacin for phagocytic killing of A. actinomycetemcomitans and found significant bacterial killing with as low as a 30:1 bacteria-to-PMN ratio. 49 The enhanced killing of bacteria by ciprofloxacin compared to clarithromycin at corresponding ratios can be partly explained by the fact that ciprofloxacin is bacteriocidal, whereas clarithromycin is mainly a bacteriostatic Clarithromycin was approved for use by the FDA in October 1991, and is traditionally used for the treatment of pneumonia, sinusitis, bronchitis, and H. pylori-associated duodenal ulcers. Clarithromycin is generally administered at an oral dose of 500 mg twice a day, with a peak serum level of 2-3 µg/ml and an elimination half-life is 5-7
hours. 19, 64 While clarithromycin has not been widely used in periodontal therapy, it is effective against A. actinomycetemcomitans and other periodontal pathogens, can reach bacteria that have invaded oral epithelium, 11 and can yield higher levels in inflamed gingiva than at healthy sites. 13 There are few side effects associated with clarithromycin, the most common being diarrhea (3%), nausea/vomiting (3%/6%), dysgeusia (3%), dyspepsia (2%), abdominal pain (2%), and headache (2 %). 67 These symptoms are relatively mild and rarely require discontinuation of drug therapy. Overall, clarithromycin seems to have promising potential for periodontal applications.
In conclusion, both HL-60 cells and mature human PMNs possess an active transporter that takes up clarithromycin and is concentrative. The transporter appears to be expressed in the early stages of myeloid maturation. The tranporter also appears to function most efficiently in an alkaline environment, which is characteristic of periodontally diseased sites. Furthermore, clarithromycin-loaded PMNs exhibit an enhanced ability to kill A. actinomycetemcomitans Y4, and its effects are most pronounced when the bacteria-to-PMN ratio is high. In combination with results from previous studies, the current findings suggest that clarithromycin could be a viable therapeutic agent for treating periodontitis cases associated with infections by A.
actinomycetemcomitans. Results are expressed as the mean of 6 determinations ± SEM. In these experiments, the indicated number of A. a. colony forming units were added to tubes containing PMNs (3 x 10 6 ), clarithromycin (5µg/ml), or PMNs loaded with clarithromycin (5µg/ml). Bacterial survival was assayed at 30 min as previously described. Half-times were calculated as described by Van Furth et al. 23 and are presented as the mean  SEM of four experiments. Within each data column, significant treatment effects were observed (P < 0.001, repeated measures ANOVA). Within columns, significant differences between pairs of incubation conditions are denoted by identical superscripts # and * (P < 0.05, Holm-Sidak Test). Transport was significantly influenced by pH (P < 0.001, ANOVA). At pH 7.8 and 8.3, the observed transport activity was similar. However, there were significant differences in all other pairwise comparisons (P < 0.05, Holm-Sidak test). 
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